Primary source: Health Canada
Donanemab, islatravir, and pegzilarginase have been added to the Prescription Drug List and are now classified as prescription drugs in Canada.
The prescription classification triggers mandatory safety monitoring and reporting processes for MAHs and limits advertising practices, influencing compliance and market behavior.
MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Classification of Donanemab, Islatravir, and Pegzilarginase as prescription drugs in Canada.
Prescription status triggers specific safety monitoring and reporting obligations for MAHs, and restricts direct-to-consumer advertising.
MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Health Canada amended the Prescription Drug List to include donanemab, islatravir, and pegzilarginase, necessitating prescription status for both human and veterinary use. This change imposes specific safety monitoring and reporting obligations on Marketing Authorization Holders (MAHs) and restricts direct-to-consumer advertising.
What changed: Donanemab, islatravir, and pegzilarginase have been added to the Prescription Drug List and are now classified as prescription drugs in Canada.
Why it matters: The prescription classification triggers mandatory safety monitoring and reporting processes for MAHs and limits advertising practices, influencing compliance and market behavior.
Practical implication: MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
